Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib versus dupilumab in children aged 2 to under 12 years with moderate to severe atopic dermatitis
CTR20244497Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of upadacitinib, dupilumab in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started Mar 2025; status: active.
02
Drugs
upadacitinibdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20244497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244497.